Table 1.
Comparison of clinical characteristics between diabetic and nondiabetic patients
| Non-diabetics (N = 62) | Type 2 diabetics (N = 38) | p value | |
|---|---|---|---|
| Age (years)* |
59.8 ± 10.3 |
61.5 ± 11.0 |
0.300 |
| Male gender (%) |
90.3 |
89.5 |
0.891 |
| BMI (Kg/m2)* |
27.9 ± 4.4 |
29.2 ± 6.9 |
0.251 |
| Previous CAD (%) |
14.5 |
31.6 |
0.075 |
| Previous MI (%) |
11.3 |
18.4 |
0.319 |
| Type of MI | |||
| STEMI vs NSTEMI (%) |
66.1/33.9 |
63.2/36.8 |
0.762 |
| Cardiovascular risk factors | |||
| Hypertension (%) |
56.5 |
84.2 |
0.004 |
| Smoking habits (%) |
61.3 |
47.4 |
0.215 |
| Family history (%) |
37.1 |
28.9 |
0.492 |
| Hyperlipidemia (%) |
71.1 |
82.3 |
0.189 |
| Physical inactivity (%) |
56.5 |
60.5 |
0.689 |
| Previous cardiovascular or antidiabetic drugs | |||
| Statins (%) |
29.0 |
31.6 |
0.825 |
| ASA (%) |
19.4 |
42.1 |
0.021 |
| ACEI (%) |
12.9 |
36.8 |
0.007 |
| ARB (%) |
12.9 |
31.6 |
0.038 |
| Beta-blockers (%) |
9.7 |
21.1 |
0.141 |
| Insulin (%) |
0.0 |
26.3 |
<0.001 |
| Oral hypoglycemic (%) |
0.0 |
65.8 |
<0.001 |
| Baseline laboratory | |||
| Admission Troponin I (μg/L)§ |
0.7 ± 5.8 |
1.5 ± 3.6 |
0.798 |
| Peak Troponin I (μg/L)§ |
55.4 ± 71.6 |
56.7 ± 64.7 |
0.793 |
| HbA1C (%)§ |
5.6 ± 0.5 |
7.1 ± 2.2 |
<0.001 |
| Admission glycemia (mg/dl)§ |
109.0 ± 31.0 |
206.5 ± 110.8 |
<0.001 |
| First fasting glycemia (mg/dl)§ |
103.0 ± 24.5 |
156.0 ± 52.5 |
<0.001 |
| Total cholesterol (mg/dl)* |
178.5 ± 59.0 |
211.7 ± 54.9 |
0.007 |
| LDL cholesterol (mg/dl)* |
113.2 ± 39.6 |
145.3 ± 44.3 |
<0.001 |
| HDL cholesterol (mg/dl)§ |
40.2 ± 9.5 |
38.7 ± 12.9 |
0.164 |
| Triglycerides (mg/dl)§ |
138.5 ± 109.5 |
148.0 ± 88.5 |
0.801 |
| Uric acid (mg/dl)* |
5.6 ± 1.3 |
6.2 ± 1.4 |
0.096 |
| Baseline creatinine (mg/dl)§ |
0.8 ± 0.3 |
0.9 ± 0.4 |
0.123 |
| Baseline hemoglobin (g/dl)* |
14.8 ± 1.4 |
14.4 ± 1.2 |
0.200 |
| Admission hs-CRP (mg/dl)* |
0.9 ± 1.3 |
1.0 ± 1.4 |
0.872 |
| LVEF (%)* |
52.6 ± 9.6 |
50.0 ± 11.8 |
0.104 |
| Hospital length of stay§ | 5.4 ± 2.6 | 5.9 ± 3.0 | 0.424 |
ACEI, Angiotensin-Converting Enzyme Inhibitors; ARB, Angiotensin II receptor blockers; ASA, acetylsalicylic acid; CAD, coronary artery disease; hs-CRP, high sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction.
*mean ± SD.
§median ± interquartile range.